Royalty Report: Drugs, Diagnostic, Biotechnology – Collection: 6801


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Diagnostic
  • Biotechnology
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6801

License Grant
Licensor and United Kingdom Licensee entered into the Collaboration Agreement relating to sequencing of expressed genes and development of practical applications therefore; and now wish to amend the Collaboration Agreement with respect to Human Diagnostic Products. The royalty obligations on Human Diagnostic Products sold by the Licensee or their Sublicensees under this Agreement shall terminate on a country-by-country and product-by-product basis on the later of ten years after first country-wide launch of each product in each country or expiration of the Collaboration Partner Patent, Licensor Patent or Licensee Diagnostic Patent, which covers the making, using or selling of such product in such country. The initial research term may be extended by the Licensee for up to five additional years on a year-by-year basis, provided  written notice is accompanied by a payment of Two Million U.S. Dollars for each additional year; and the Licensee has extended the initial research term of the June 1996 License Agreement for the same period of time.

Licensor hereby grants to Licensee a non-exclusive, world-wide license under Licensor Special Technology, claims of Licensor Patents that cover Licensor Special Technology and Collaboration Partner Patents to perform research and development of Human Diagnostic Products during the Initial Research Term and Research Term Extensions pursuant to this Agreement, provided however that Licensor will not have a license to make, have made, use and sell a Human Diagnostic Product based on Licensor  diagnostic research except as described herein.

License Property
Antibody Product shall mean an antibody monoclonal or polyclonal and fragments and constructs thereof which may be useful for the treatment or prevention of a disease or disorder in humans.

Gene shall mean a eDNA or a human gene or a family of such human genes or any portion of such cDNA, gene or genes.

Field of Use
Human Diagnostic Product are potentially useful for the diagnosis of a specific disease, condition, prognostic determination, treatment outcome or other indication of human health status.

IPSCIO Record ID: 942

License Grant
Effective upon Licensee’s election to acquire a commercial license, Licensor grants to Licensee and its Affiliates the following licenses: an exclusive, worldwide, non-transferable royalty bearing license under the Licensor Technology with the right to sublicense, to use hybridomas delivered by Licensor to Licensee to make or have made Antibodies, and an exclusive, worldwide, non-transferable royalty bearing license under the Technology with the right to sublicense, to use Antibodies made in the Research to make, have made, import, have imported, use, offer for sale and sell Products.

Product shall mean any product for the treatment or diagnosis of human disease containing an Antibody provided by Licensor or produced from any hybridoma provided by Licensor or a portion thereof.

License Property
Licensor is the sole and exclusive owner of certain transgenic Mice useful for the preparation of fully human monoclonal antibodies.
Field of Use
Licensee desires to have Licensor conduct research with the Mice for the development of fully human monoclonal antibodies to certain Antigens and to evaluate the utility of such antibodies as potential therapeutics involved in fibrosis or fibroproliferative disease.

IPSCIO Record ID: 3283

License Grant
The University hereby grants the Licensee an exclusive worldwide right and license in the Licensed field to practice under the Patent Rights and the Technology Rights and to make, have made, use, offer for sale, sell and import Licensed products or the practice of services utilizing the Licensed Processes. Licensee shall have an exclusive option to license any Invention. Licensee
shall have the right to grant sublicenses consistent with this Agreement.
License Property
United States Patent   7,668,659
Diagnosis and classification of multiple myeloma

United States Patent   7,308,364
Diagnosis of multiple myeloma on gene expression profiling

Field of Use
Licensed Field shall mean those applications of Patent Rights and/or the Technology Rights with respect to non-malignant and malignant human or animal pathologies, including but not limited to, determining and/or identifying the presence, predisposition, effect of treatment, mode or type of treatment, type of patient, susceptibility to treatment or prevention, progress of treatment, current and predicted clinical outcome, and/or therapeutic or prophylactic treatment and/or regimen.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.